Blue Jet Healthcare Ltd (BLUEJET) Q1FY26 Concall Summary - Jun-2025 Qtr
Performance Overview
- Blue Jet Healthcare started FY26 with strong momentum, continuing the trend from H2 FY25.
- Q1 FY26 revenue reached 3,154.8 million, a 4% sequential increase and a substantial 118% year-over-year growth. This growth was fueled by consistent volume increases across PI/API and contrast media platforms.
- EBITDA for Q1 FY26 was 1,210 million, with a margin of 34%, slightly lower than the previous quarter due to production inventory phasing and product mix.
- PAT for the quarter reached 912 million, reflecting a net margin of 25.7%. Year-over-year, EBITDA and PAT saw impressive growth of 178% and 114%, respectively, driven by volume expansion and improved operational scale.
- The company maintains a healthy operating cash flow and continues disciplined capital deployment in R&D and capacity expansion.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.